{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-000064","form_type":"8-K","ticker":"CFOR","cik":"0001293818","company_name":"CapForce Inc.","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.258222+00:00","generated_at":"2026-06-20T16:27:35.533579+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"OpGen closes $7.5M public offering of common stock and warrants","bullets":["Sold 2,586,207 shares/common or pre-funded warrants, plus Series A-1 and A-2 warrants at $2.90 per combined unit.","Gross proceeds approximately $7.5M; net proceeds to fund commercialization of Acuitas AMR Gene Panel and Unyvero Platform.","Proceeds also allocated to Ares Genetics development, sales/marketing, manufacturing infrastructure, and debt repayment.","H.C. Wainwright acted as exclusive placement agent, receiving 6.0% cash fee.","Offering closed on January 11, 2023 under effective S-1 registration statement (File No. 333-268648)."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-000064","json":"https://secwatch.observer/filing/0001079973-23-000064.json","markdown":"https://secwatch.observer/filing/0001079973-23-000064.md","text":"https://secwatch.observer/filing/0001079973-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/0001079973-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/opgen_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:27:35.533579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4178b9cb277daf9760b89e333b51315bd7f002b6","claim":"CapForce Inc. entered into Purchase Agreement with a certain institutional investor valued at aggregate gross proceeds of approximately $7.50 million (effective 2023-01-06).","evidence_excerpt":"On January 6, 2023, OpGen, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000064/0001079973-23-000064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Value","value":"aggregate gross proceeds of approximately $7.50 million"},{"label":"Effective","value":"2023-01-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}